Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial.
Nadine SchurSalvatore BrugalettaAngel CequierAndrés IñiguezAntonio SerraPilar Jiménez-QuevedoVicente MainarGianluca CampoMaurizio TespiliPeter den HeijerArmando BethencourtNicolás VazquezMarco ValgimigliPatrick W SerruysZanfina AdemiMatthias SchwenkglenksManel Sabaté TenasPublished in: PloS one (2018)
Despite higher total costs relative to BMS, EES appeared to be a cost-effective therapy for ST-segment elevation myocardial infarction patients due to their incremental effectiveness. Predicted incremental cost-effectiveness ratios were below generally acceptable threshold values.
Keyphrases
- st segment elevation myocardial infarction
- percutaneous coronary intervention
- randomized controlled trial
- end stage renal disease
- coronary artery disease
- acute coronary syndrome
- newly diagnosed
- ejection fraction
- chronic kidney disease
- study protocol
- systematic review
- prognostic factors
- peritoneal dialysis
- patient reported outcomes